New Drugs News
-
Money manager Tim McCarthy has worked in the U.S., Russia and Switzerland, and has seen doctors in all three countries for Hashimoto disease, a condition in which his immune system attacks his thyroid. He has no doubt which health system is best.
-
Two drugs from Bristol-Myers Squibb Co. shrank tumors in as many as half of patients with advanced melanoma, according to early research that may pave the way for cocktails that trigger the immune system to destroy cancer.
-
Primecap Odyssey Aggressive Growth Fund, run by a firm that’s best known as a money manager for Vanguard Group Inc., beat peers over the past five years with a heavy dose of health-care stocks, many held for years.
-
Most U.S. stocks fell, after benchmark indexes climbed to record levels last week, even as government data showed retail sales unexpectedly rose in April.
-
Elan Corp. agreed to pay $1 billion for a share of the royalties on new drugs from Theravance Inc. as the Irish drugmaker tries to persuade shareholders to spurn a takeover offer by Royalty Pharma.
-
Ten-year Treasury yields reached the highest level since March as retail sales unexpectedly rose, while the Standard & Poor’s 500 Index was little changed at a record level. The dollar rallied and oil fell for a third day.
-
Michael J. Fox left prime-time television more than a decade ago to focus on his battle with Parkinson’s disease. Now he’s back, with the help of drugs that keep his own shaking from the illness mostly under control.
-
Merck & Co., Bristol-Myers Squibb Co. and Roche Holding AG have opened a new front against cancer with the next generation of experimental drugs that use the human immune system to seek and destroy tumor cells.
-
Eli Lilly & Co. halted development of an experimental cancer drug after the medicine failed to lengthen survival for certain lymphoma patients in a study.
-
Bayer AG’s first-quarter profit fell short of analysts’ estimates as a crop of new medicines struggled to offset lagging older drugs and plunging earnings at the plastics unit.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page